nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3273Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESФармакокинетика циклоспорина А в составе препарата биорала у больных после аллотрансплантации почкиPharmacokinetics cyclosporin A (Bioral) in kidney transplant recipientsБарановаФ. С.BaranovaF. S.noemail@neicon.ruМелюковаЮ. Ф.MelukovaJ. F.noemail@neicon.ruПоповаЛ. К.PopovaL. K.noemail@neicon.ruКорсаковаТ. В.KorsakovaT. V.noemail@neicon.ruКотенкоО. Н.KotenkoO. N.noemail@neicon.ruРжевскаяО. Н.RjevskayaO. N.noemail@neicon.ruТарабаркоН. В.TarabarkoN. V.noemail@neicon.ruМойсюкЯ. Г.MoisukY. G.noemail@neicon.ruНИИ трансплантологии и искусственных органов МЗ РФRussian Federation20012806202534451453Copyright © Баранова Ф.С., Мелюкова Ю.Ф., Попова Л.К., Корсакова Т.В., Котенко О.Н., Ржевская О.Н., Тарабарко Н.В., Мойсюк Я.Г., 20252025Баранова Ф.С., Мелюкова Ю.Ф., Попова Л.К., Корсакова Т.В., Котенко О.Н., Ржевская О.Н., Тарабарко Н.В., Мойсюк Я.Г.Baranova F.S., Melukova J.F., Popova L.K., Korsakova T.V., Kotenko O.N., Rjevskaya O.N., Tarabarko N.V., Moisuk Y.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3273

В последние годы в клиническую практику внедряются новые препараты циклоспорина А (CsA), сведения о фармакокинетике (ФК) и клинической эффективности которых ограничены. Цель данной работы: описать ФК СsA в составе микроэмульсионной лекарственной формы - биорала (Panimmune Bioral TM Panacea Biotech). У 24 больных после аллотрансплантации почки были определены С0, Сmax, Tmax, AUC0-12, AUC0-4. Полученные нами данные свидетельствуют о том, что биорал по своим ФК-характеристикам не имеет принципиальных отличий от неорала.

During the last years in clinical practice has used a few new drug formulations of cyclosporine A (CsA).The aim of this study was to describe pharmacokinetic properties of Cs microemulsion, bioral (Panimmune Bioral TM Panacea Biotech).We determined in 24 patients after kidney transplantation C0, Cmax, Tmax, AUC0-12, AUC0-4. These results suggests that bioral have the same FK properties that neoral.

циклоспорин Абиоралфармакокинетикатрансплантация почкиReferencesBelitsky P. Neoral use in the renal Transplant recipient. Transplantation Proceedings. 2000; 32; 3A: 10S-19S.Belitsky P. Neoral use in the renal Transplant recipient. Transplantation Proceedings. 2000; 32; 3A: 10S-19S.Levy G. Introduction. Transplantation Proceedings. 2000; 32; 3A: 1S.Levy G. Introduction. Transplantation Proceedings. 2000; 32; 3A: 1S.Mahalati K., Barry D. Kahan. Advancing the art of immunosuppression with the science of pharmacology. Current opinion in organ transplantation. 2000; 5; 3: 255.Mahalati K., Barry D. Kahan. Advancing the art of immunosuppression with the science of pharmacology. Current opinion in organ transplantation. 2000; 5; 3: 255.Levy G.A. C2 monitoring strategy for optimizing cyclosporin immunosuppression from Neoral formulation. BioDrug. 2001; 15 (5): 279-290.Levy G.A. C2 monitoring strategy for optimizing cyclosporin immunosuppression from Neoral formulation. BioDrug. 2001; 15 (5): 279-290.Singh S., Sharma D.R. A review of absorption characteristic of microemulsion cyclosporin product over the last 2 year in indian subject. J Indian Med Association. 1999; 97 (3): 114-117.Singh S., Sharma D.R. A review of absorption characteristic of microemulsion cyclosporin product over the last 2 year in indian subject. J Indian Med Association. 1999; 97 (3): 114-117.Singh S., Sharma D.R. Evaluation of kidney function and cyclosporin level in renal transplant recipient on Panimmune Bioral in post transplant period. J Indian Med Association. 1999 May; 97 (5): 204-205.Singh S., Sharma D.R. Evaluation of kidney function and cyclosporin level in renal transplant recipient on Panimmune Bioral in post transplant period. J Indian Med Association. 1999 May; 97 (5): 204-205.Amante A.S., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporin microemulsion therapy in the immediate posttransplant period. Transpl Proc. 1996; 28 (4): 2162-2163.Amante A.S., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporin microemulsion therapy in the immediate posttransplant period. Transpl Proc. 1996; 28 (4): 2162-2163.David O.J., Johnston A. Limited sampling strategy for estimation cyclosporin area under the concentration-time curve: review of current algoritm. Therapeutic Drug monitoring. 2001; 23 (2): 100-114.David O.J., Johnston A. Limited sampling strategy for estimation cyclosporin area under the concentration-time curve: review of current algoritm. Therapeutic Drug monitoring. 2001; 23 (2): 100-114.Gaspari F., Anedda M.F., Signorini O., Romuzzi G., Perico N. Prediction of cyclosporine area under the curve using three-point sampling strategy after neoral administration. J Amer Soc Nephrol. 1997; 647-652.Gaspari F., Anedda M.F., Signorini O., Romuzzi G., Perico N. Prediction of cyclosporine area under the curve using three-point sampling strategy after neoral administration. J Amer Soc Nephrol. 1997; 647-652.Belitsky P., Dunn S., A.J., Johnston A., Levy G. Impact of Absorbtion Profiling on efficacy and safety of cyclosporin Therapy in transplant recipients. Clinical Pharmacokinetic. 2000; 39 (2).Belitsky P., Dunn S., A.J., Johnston A., Levy G. Impact of Absorbtion Profiling on efficacy and safety of cyclosporin Therapy in transplant recipients. Clinical Pharmacokinetic. 2000; 39 (2).Kahan B.D., Dunn J. et al. Reduced inter- and intrasubject variability in cyclosporin pharmacokinetics in renal transplant recipient treated with microemulsion formulation in conjuction with fasting, low fat meal, or high fat meals. Transplantation. 1995; 59: 505-11.Kahan B.D., Dunn J. et al. Reduced inter- and intrasubject variability in cyclosporin pharmacokinetics in renal transplant recipient treated with microemulsion formulation in conjuction with fasting, low fat meal, or high fat meals. Transplantation. 1995; 59: 505-11.

The authors declare that there are no conflicts of interest present.